Jue, 11 Abr 2024
Oculis announces a successful $59 million funding round and its upcoming debut on Nasdaq Iceland.
Oculis Holding AG an eye care solution firm, has successfully completed a $59 million financing round on April 11, 2024, with its shares set to be traded on Nasdaq Iceland’s Main Market. Según un comunicado de prensa.
This move was backed by new Icelandic investors, ensuring Oculis’s operational and capital financial stability through the Q4 of 2026.
The Icelandic Central Bank Financial Supervision has greenlit Oculis’s prospectus for its ordinary shares’ admission to the Nasdaq Iceland Main Market.
The exact trading commencement date will be announced soon, enhancing Oculis’s visibility in the global market.
This financial milestone coincides with Oculis’s anticipation of revealing Q2 2024 topline results from the “OCS-02 Phase 2b RELIEF trial for Dry Eye Disease”, showcasing the company’s continued innovation in eye care.
With its shares already listed on the Nasdaq in the U.S. under “OCS,” Oculis’s dual-listing displays confidence.
The funds from this latest round will fuel the advancement of Oculis’s clinical development pipeline, emphasising its mission to transform eye care and patient outcomes worldwide.
Spanish 
English 
German 
French 
Arabic